We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of ...

Merck (MRK) ended the recent trading session at $94, demonstrating a +0.87% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.78%. Meanwhile, ...

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.